Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis

Binlong Chen; Yanzhong Zhao; Zichang Lin; Jiahao Liang; Jialong Fan; Yanyan Huang; Leye He; Bin Liu

doi:10.1016/j.jpha.2023.11.011

Volume 14 Issue 5

May 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2024 > 14(5): 100904

Binlong Chen, Yanzhong Zhao, Zichang Lin, Jiahao Liang, Jialong Fan, Yanyan Huang, Leye He, Bin Liu. Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis[J]. Journal of Pharmaceutical Analysis, 2024, 14(5): 100904. doi: 10.1016/j.jpha.2023.11.011

Citation:

Binlong Chen, Yanzhong Zhao, Zichang Lin, Jiahao Liang, Jialong Fan, Yanyan Huang, Leye He, Bin Liu. Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis[J]. Journal of Pharmaceutical Analysis, 2024, 14(5): 100904. doi: 10.1016/j.jpha.2023.11.011

Citation:

Binlong Chen, Yanzhong Zhao, Zichang Lin, Jiahao Liang, Jialong Fan, Yanyan Huang, Leye He, Bin Liu. Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis[J]. Journal of Pharmaceutical Analysis, 2024, 14(5): 100904. doi: 10.1016/j.jpha.2023.11.011

PDF( 7887 KB)

Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis

doi: 10.1016/j.jpha.2023.11.011

a. Health Management Center, The Third Xiangya Hospital, Central South University, Changsha, 410013, China;
b. Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China;
c. Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, China;
d. College of Biology, Hunan University, Changsha, 410082, China

Funds:

This work was partially supported by Changsha Municipal Natural Science Foundation (Grant No.: kq2014265), the Construction Program of Hunan's innovative Province (CN)-High-tech Industry Science and Technology Innovation Leading Project (Project No.: 2020SK2002), the Natural Science Foundation of Hunan Province (Grant No.: 2023JJ40130), Postgraduate Scientific Research Innovation Project of Hunan Province (Project No.: CX20230317), and the Changsha Platform and Talent Plan (kq2203002).

Received Date: Sep. 14, 2023
Accepted Date: Nov. 21, 2023
Rev Recd Date: Nov. 09, 2023
Publish Date: May 30, 2024

Abstract

Abstract

Due to the non-targeted release and low solubility of anti-gastric cancer agent, apatinib (Apa), a first-line drug with long-term usage in a high dosage often induces multi-drug resistance and causes serious side effects. In order to avoid these drawbacks, lipid-film-coated Prussian blue nanoparticles (PB NPs) with hyaluronan (HA) modification was used for Apa loading to improve its solubility and targeting ability. Furthermore, anti-tumor compound of gamabufotalin (CS-6) was selected as a partner of Apa with reducing dosage for combinational gastric therapy. Thus, HA-Apa-Lip@PB-CS-6 NPs were constructed to synchronously transport the two drugs into tumor tissue. In vitro assay indicated that HA-Apa-Lip@PB-CS-6 NPs can synergistically inhibit proliferation and invasion/metastasis of BGC-823 cells via downregulating vascular endothelial growth factor receptor (VEGFR) and matrix metalloproteinase-9 (MMP-9). in vivo assay demonstrated strongest anti-tumor growth and liver metastasis of HA-Apa-Lip@PB-CS-6 NPs administration in BGC-823 cells-bearing mice compared with other groups due to the excellent penetration in tumor tissues and outstanding synergistic effects. In summary, we have successfully developed a new nanocomplexes for synchronous Apa/CS-6 delivery and synergistic gastric cancer (GC) therapy.
- Apatinib,
- Gamabufotalin,
- Lipid/Prussian blue nanoparticles,
- Gastric cancer

FullText(HTML)

References(47)

References

[1]	E.C. Smyth, M. Nilsson, H.I. Grabsch, et al., Gastric cancer, Lancet. 396 (2020) 635-648.
[2]	F.M. Johnston, M. Beckman, Updates on management of gastric cancer, Curr. Oncol. Rep. 21 (2019), 67.
[3]	N. Charalampakis, P. Economopoulou, I. Kotsantis, et al., Medical management of gastric cancer: A 2017 update, Cancer Med. 7 (2018) 123-133.
[4]	Y.Y. Choi, J.H. Cheong, Beyond precision surgery: Molecularly motivated precision care for gastric cancer, Eur. J. Surg. Oncol. 43 (2017) 856-864.
[5]	J. Ding, X. Chen, X. Dai, et al., Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study, J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 895-896 (2012) 108-115.
[6]	J. Li, X. Zhao, L. Chen, et al., Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies, BMC Cancer. 10 (2010), 529.
[7]	S. Tian, H. Quan, C. Xie, et al., YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo, Cancer Sci. 102 (2011) 1374-1380.
[8]	R. Geng, L. Song, J. Li, et al., The safety of apatinib for the treatment of gastric cancer, Expet Opin. Drug Saf. 17 (2018) 1145-1150.
[9]	G. Roviello, A. Ravelli, K. Polom, et al., Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer, Cancer Lett. 372 (2016) 187-191.
[10]	J. Ding, X. Chen, Z. Gao, et al., Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans, Drug Metab. Dispos. 41 (2013) 1195-1210.
[11]	J.A. Ajani, T.A. D’Amico, D.J. Bentrem, et al., Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology, J. Natl. Compr. Cancer Netw. 20 (2022) 167-192.
[12]	N. Tang, L. Shi, Z. Yu, et al., Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway, Oncotarget. 7 (2016) 3533-3547.
[13]	Y.B.L. Moreno, A. Katz, W. Miklos, et al., Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K+-ATPase, Mol. Cancer 12 (2013), 33.
[14]	J. Fan, B. Liu, Y. Long, et al., Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition, Acta Biomater. 113 (2020) 554-569.
[15]	B. Yuan, R. Shimada, K. Xu, et al., Multiple cytotoxic effects of gamabufotalin against human glioblastoma cell line U-87, Chem. Biol. Interact. 314 (2019), 108849.
[16]	S. Nagini, Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention, World J. Gastrointest. Oncol. 4 (2012) 156-169.
[17]	H. Wong, T. Yau, Targeted therapy in the management of advanced gastric cancer: Are we making progress in the era of personalized medicine?, Oncol. 17 (2012) 346-358.
[18]	Y. Ke, J. Zhu, Y. Chu, et al., Bifunctional fusion membrane-based hydrogel enhances antitumor potency of autologous cancer vaccines by activating dendritic cells, Adv. Funct. Mater. 32 (2022), 2201306.
[19]	Q. Liu, D. Zhang, H. Qian, et al., Superior antitumor efficacy of IFN-alpha2b-incorporated photo-cross-linked hydrogels combined with T cell transfer and low-dose irradiation against gastric cancer, Int. J. Nanomed. 15 (2020) 3669-3680.
[20]	D. Zhang, Y. Chu, H. Qian, et al., Antitumor activity of thermosensitive hydrogels packaging gambogic acid nanoparticles and tumor-penetrating peptide iRGD against gastric cancer, Int. J. Nanomed. 15 (2020) 735-747.
[21]	W. Chen, K. Shi, J. Liu, et al., Sustained co-delivery of 5-fluorouracil and cis-platinum via biodegradable thermo-sensitive hydrogel for intraoperative synergistic combination chemotherapy of gastric cancer, Bioact. Mater. 23 (2023) 1-15.
[22]	X. Cai, W. Gao, M. Ma, et al., A prussian blue-based core-shell hollow-structured mesoporous nanoparticle as a smart theranostic agent with ultrahigh pH-responsive longitudinal relaxivity, Adv. Mater. 27 (2015) 6382-6389.
[23]	J. Liang, C. Wang, J. Fan, et al., Hybrid membrane-camouflaged hollow prussian blue nanoparticles for shikonin loading and combined chemo/photothermal therapy of metastatic TNBC, Materials Today Advances. 14 (2022), 100245.
[24]	C. Tong, X. Zhong, Y. Yang, et al., PB@PDA@Ag nanosystem for synergistically eradicating MRSA and accelerating diabetic wound healing assisted with laser irradiation, Biomaterials. 243 (2020), 119936.
[25]	B. Liu, W. Wang, J. Fan, et al., RBC membrane camouflaged prussian blue nanoparticles for gamabutolin loading and combined chemo/photothermal therapy of breast cancer, Biomaterials. 217 (2019), 119301.
[26]	C. Xiao, C. Tong, J. Fan, et al., Biomimetic nanoparticles loading with gamabutolin-indomethacin for chemo/photothermal therapy of cervical cancer and anti-inflammation, J. Contr. Release 339 (2021) 259-273.
[27]	E. Sackmann, Supported membranes: scientific and practical applications, Science. 271 (1996) 43-48.
[28]	R.H. Tammi, A. Kultti, V.M. Kosma, et al., Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan, Semin. Cancer Biol. 18 (2008) 288-295.
[29]	A. Ianevski, A.K. Giri, T. Aittokallio, SynergyFinder 2.0: visual analytics of multi-drug combination synergies, Nucleic Acids Res. 48 (2020) W488-W493.
[30]	H. Meng, M. Wang, H. Liu, et al., Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice, ACS Nano 9 (2015) 3540-3557.
[31]	H. Zhou, P. You, H. Liu, et al., Artemisinin and Procyanidins loaded multifunctional nanocomplexes alleviate atherosclerosis via simultaneously modulating lipid influx and cholesterol efflux, J. Contr. Release 341 (2022) 828-843.
[32]	Y. Long, Z. Wang, J. Fan, et al., A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway, J. Mater. Chem. B 9 (2021) 3838-3855.
[33]	Q. Xie, B. Li, J. Fan, et al., Biomimetic hybrid-cell membrane nanoparticles loaded with panaxytriol for breast cancer combinational therapy, Mater. Des. 223 (2022), 111219.
[34]	Z. Lei, J. Fan, X. Li, et al., Biomimetic graphene oxide quantum dots nanoparticles targeted photothermal-chemotherapy for gastric cancer, J. Drug Target. 31 (2023) 320-333.
[35]	J. Fan, Y. Qin, C. Xiao, et al., Biomimetic PLGA-based nanocomplexes for improved tumor penetration to enhance chemo-photodynamic therapy against metastasis of TNBC, Materials Today Advances. 16 (2022), 100289.
[36]	J.R. Casey, S. Grinstein, J. Orlowski, Sensors and regulators of intracellular pH, Nat. Rev. Mol. Cell Biol. 11 (2010) 50-61.
[37]	G. Liu, X. Zhao, Y. Zhang, et al., Engineering biomimetic platesomes for pH-responsive drug delivery and enhanced antitumor activity, Adv. Mater. 31 (2019), 1900795.
[38]	T.M. Allen, P.R. Cullis, Liposomal drug delivery systems: from concept to clinical applications, Adv. Drug Deliv. Rev. 65 (2013) 36-48.
[39]	L.J. Deng, Y. Li, M. Qi, et al., Molecular mechanisms of bufadienolides and their novel strategies for cancer treatment, Eur. J. Pharmacol. 887 (2020), 173379.
[40]	W. Muller, T. Noguchi, H.C. Wirtz, et al., Expression of cell-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer, J. Pathol. 189 (1999) 186-193.
[41]	A. Dongre, R.A. Weinberg, New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer, Nat. Rev. Mol. Cell Biol. 20 (2019) 69-84.
[42]	Z. Yu, W. Guo, X. Ma, et al., Gamabufotalin, a bufadienolide compound from toad venom, suppresses COX-2 expression through targeting IKKβ/NF-κB signaling pathway in lung cancer cells, Mol. Cancer 13 (2014), 203.
[43]	Q. Zhang, C. Deng, Y. Fu, et al., Repeated administration of hyaluronic acid coated liposomes with improved pharmacokinetics and reduced immune response, Mol. Pharm. 13 (2016) 1800-1808.
[44]	A. Schroeder, D.A. Heller, M.M. Winslow, et al., Treating metastatic cancer with nanotechnology, Nat. Rev. Cancer 12 (2011) 39-50.
[45]	D.X. Nguyen, P.D. Bos, J. Massague, Metastasis: from dissemination to organ-specific colonization, Nat. Rev. Cancer 9 (2009) 274-284.
[46]	Z. Zhang, B. Niu, J. Chen, et al., The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer, Biomaterials. 35 (2014) 4565-4572.
[47]	J. Wolfram, M. Zhu, Y. Yang, et al., Safety of nanoparticles in medicine, Curr. Drug Targets. 16 (2015) 1671-1681.